Welcome to LookChem.com Sign In|Join Free

CAS

  • or

72517-19-2

Post Buying Request

72517-19-2 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

72517-19-2 Usage

Physical appearance

Yellow crystalline powder

Usage

Reagent in biochemical and organic synthesis

Chemical structure

Derivative of benzoic acid with two hydroxyl (-OH) groups and a nitro (-NO2) group attached to the benzene ring

Applications

Preparation of pharmaceuticals, chelating agent in metal ion detection assays

Known properties

Antioxidant, antimicrobial

Valued in fields

Medicine, food preservation, cosmetics

Check Digit Verification of cas no

The CAS Registry Mumber 72517-19-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,5,1 and 7 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 72517-19:
(7*7)+(6*2)+(5*5)+(4*1)+(3*7)+(2*1)+(1*9)=122
122 % 10 = 2
So 72517-19-2 is a valid CAS Registry Number.

72517-19-2SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,3-dihydroxy-4-nitrobenzoic acid

1.2 Other means of identification

Product number -
Other names 4-Nitro-2,3-dihydroxy-benzoesaeure

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:72517-19-2 SDS

72517-19-2Relevant articles and documents

NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION

-

Page/Page column 133, (2011/07/06)

The embodiments provide compounds of the general Formulae I, II, III, IV, or V as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 72517-19-2